Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis-Reference-Cited by-同舟云学术

Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis

Published:2017-10-16 Issue:4 Volume:103 Page:582-590
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Ogungbenro Kayode¹,Patel Alkesh²,Duncombe Robert²,Nuttall Richard³,Clark James²,Lorigan Paul²⁴

Affiliation:

1. Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and HealthUniversity of Manchester, Manchester Academic Health Science CentreManchester United Kingdom

2. The Christie NHS Foundation TrustManchester United Kingdom

3. The Royal Marsden NHS Foundation TrustLondon United Kingdom

4. Institute of Molecular and Clinical Cancer SciencesUniversity of Manchester

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.875

Reference34 articles.

1. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

2. Pembrolizumab

3. Pembrolizumab: First Global Approval

4. KEYTRUDA (pembrolizumab) [package inserts]. Merck & Co. (2016). Accessed 27 January2016.

5. OPDIVO (nivolumab) [package inserts] Bristol‐Myers Squibb. (2016). Accessed 13 February 2017.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ELISA assay for the quantification of ipilimumab in human serum, plasma, milk, and cerebrospinal fluid;Journal of Pharmaceutical and Biomedical Analysis;2024-08

2. Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran;Expert Review of Pharmacoeconomics & Outcomes Research;2023-09-27

3. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer;Journal of Oncology Pharmacy Practice;2023-09-01

4. Pembrolizumab for the adjuvant treatment of IIB or IIC melanoma;Expert Review of Anticancer Therapy;2023-08-13

5. Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions;Health Affairs;2023-07-01